The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4⁺ T cells. [1]

In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. [2]

A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. [3]

Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. [4]

Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. [5]

The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. [6]

Mometasone Furoate Suppresses PMA-Induced MUC-5AC and MUC-2 Production in Human Airway Epithelial Cells. [7]

References:

[1] S.P.Umland, et al, J. Allergy Clin. Immunol., 1997, 100(4), pp 511-519.

[2] C.L.Smith, et al, Arzneimi Helforschung, 1998, 48(9), pp 956-960.

[3] C.Crim, et al, Clin. Ther., 2001, 23(9), pp 1339-1354.

[4] A.M.Wilson, et al, Clin. Exp. Allergy, 2001, 31(1), pp 61-68.

[5] K.P.Madauss, et al, J. Med. Chem., 2004, 47(13), pp 3381-3387.

[6] I.T. Bijsmans, et al, Sci. Rep., 2015, 5(14086), pp 1-12.

[7] O. Poachanukoon, et al, Tuberc. Respir. Dis.(Seoul), 2017, 80(1), pp 60-68.